# A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07787520/  
OnCo record `nct07787520` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of LAE118 run by Laekna Limited, not yet recruiting.

## Summary

A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors is a phase 1 interventional study registered as NCT07787520 by Laekna Limited, with 150 participants planned, started 2026-08, primary completion expected 2029-03. Conditions recorded: Patients With Advanced Solid Tumors. Interventions recorded: LAE118, Fulvestrant, Palbociclib.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07787520
- Phase: 1
- Setting: A Phase I, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LAE118 as Monotherapy and in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors
- Sponsor: Laekna Limited
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07787520: https://clinicaltrials.gov/study/NCT07787520

## Connected records

- drugs: [LAE118](https://onco.cc/drugs/lae118/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07787520.json